Aandeel A085660 CHABIOTECH CO.,LTD.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Chabiotech Co.,Ltd.

Aandelen

A085660

KR7085660009

slotkoers Korea S.E.
Andere beurzen
 00:00:00 08-05-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
17.420 KRW +0,11% Intraday-grafiek van Chabiotech Co.,Ltd. +1,81% -11,08%
2023 CHA Biotech Co., Ltd. Rapporteert winstresultaten voor het eerste kwartaal eindigend op 31 maart 2023 CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
CHA Biotech to Partner with Subsidiary to Advance NK Cell Therapy
CHA Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Chronic Lower Back Pain Pipeline Offers Novel Treatment Options | 10+ Companies & 10+ Drugs
CHA Biotech : Unit Signs Contract with Sartorius for Viral Vectors Process Technology
CHA Biotech Co., Ltd. announced that it has received KRW 75 billion in funding from a group of investors
CHA Biotech Co., Ltd. announced that it expects to receive KRW 75 billion in funding from a group of investors
Astellas Institute for Regenerative Medicine acquired remaining 50% stake in Stem Cell & Regenerative Medicine International, Inc from CHA Biotech Co., Ltd. for $46.7 million.
Chabiotech To Divest Biotechnology And Medicine And Medical Supplies
Sorrento Therapeutics to Form Joint Venture with CHA Biotech Co
Sorrento Therapeutics, Inc. to Form Joint Venture with CHA Biotech Co., Ltd. to Develop and Commercialize Natural Killer Cell Therapies
CHA Biotech Co., Ltd. announced that it has received KRW 44 billion in funding from a group of investors
CHA Biotech Co., Ltd. announced that it expects to receive KRW 44 billion in funding from Kyunghee Industry Co. Ltd. and other investors
Closed Merger/Acquisition Transaction – Target: Chadiostech Co., Ltd.; Buyer(s): Da Vinci Capital Management Ltd., The European Bank for Reconstruction and Development, Investment Arm; Seller(s): CHA Biotech Co., Ltd., Kyunghee Industry Co. Ltd., Sungkwang Medical Foundation, Endowment Arm; Transaction Size: KRW23503.27 mm
The Da Vinci CIS Private Sector Growth Fund (Fund I), Da Vinci Eurasian Financial Infrastructure Fund (Fund II) and Da Vinci No. 3 Investment Fund (Fund III) of Da Vinci Capital Management Ltd. and The European Bank for Reconstruction and Development, Investment Arm, Chang-Mi Bin, Jung-Seok Oh and Jung-Seok Kang entered into a contract to acquire 22.66% stake in Chadiostech Co., Ltd. from Gwang-Yeol Cha, 8 other individuals, CHA Biotech Co., Ltd., Kyunghee Indus
CHA Healthcare Operation Co., Ltd. cancelled the acquisition of Cha Medical Service Co., Ltd. from CHA Bio&Diostech Inc. and others.
CHA-Meditech Co., Ltd. acquired CHA-BioMed Co. Ltd from CHA Bio&Diostech Inc. and other sellers.
CHA Healthcare Operation Co., Ltd. agreed to acquire Cha Medical Service Co., Ltd. from CHA Bio&Diostech Inc. and others.
CHA Bio & Diostech Co., Ltd. completed the spin-off of camera lens and optical science business division for KRW 140 billion
CHA Bio & Diostech Co., Ltd. agreed to spin-off camera lens and optical science business division.
Cha Bio&Diostech Files Investigational New Drug with Korean FDA for PLX Cells
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers A085660
  4. Nieuws Chabiotech Co.,Ltd.
  5. Andere talen